Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC

Tony Mok, Shirish M. Gadgeel, E.S. Kim, Vamsidhar Velcheti, Sylvia Hu, Todd Riehl, Erica Schleifman, Satabdi Paul, Simonetta Mocci, David S. Shames,

Annals of Oncology · 2017 · 16 citations · 0 references

DOIFull text

Open access

Concepts